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AbstrAct
Introduction The European Centre for Disease Prevention 
and Control is developing evidence-based guidance for 
voluntary screening, treatment and vaccine prevention 
of infectious diseases for newly arriving migrants to the 
European Union/European Economic Area. The objective 
of this systematic review protocol is to guide the 
identification, appraisal and synthesis of the best available 
evidence on prevention and assessment of the following 
priority infectious diseases: tuberculosis, HIV, hepatitis B, 
hepatitis C, measles, mumps, rubella, diphtheria, tetanus, 
pertussis, poliomyelitis (polio), Haemophilus influenza 
disease, strongyloidiasis and schistosomiasis.
Methods and analysis The search strategy will identify 
evidence from existing systematic reviews and then 
update the effectiveness and cost-effectiveness evidence 
using prospective trials, economic evaluations and/or 
recently published systematic reviews. Interdisciplinary 
teams have designed logic models to help define study 
inclusion and exclusion criteria, guiding the search 
strategy and identifying relevant outcomes. We will 
assess the certainty of evidence using the Grading 
of Recommendations Assessment, Development and 
Evaluation (GRADE) approach.
Ethics and dissemination There are no ethical or 
safety issues. We anticipate disseminating the findings 
through open-access publications, conference abstracts 
and presentations. We plan to publish technical 
syntheses as GRADEpro evidence summaries and 
the systematic reviews as part of a special edition 
open-access publication on refugee health. We are 
following the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses for Protocols reporting 
guideline. This protocol is registered in PROSPERO: 
CRD42016045798.
IntroductIon
The increase in refugees and other migrants 
from low-income and middle-income coun-
tries (LMICs) to the European Union/Euro-
pean Economic Area (EU/EEA) since 20111 
has made the development of infectious 
disease guidance a public health priority 
for EU/EEA Member States. High mobility, 
poor living conditions, barriers to accessing 
healthcare and potential public health risks 
for newly arriving migrant populations and 
host populations are leading public health 
concerns. As a result, the European Centre 
for Disease Prevention and Control (ECDC) 
called for evidence-based guidance to support 
tailored public health approaches to health 
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Protocol
strengths and limitations of this study
 ► Explicit, transparent and trustworthy review method.
 ► Pragmatic approach builds on existing systematic 
reviews and permits de novo reviews when 
warranted.
 ► International team with guideline, Grading of 
Recommendations Assessment, Development and 
Evaluation migrant health, and infectious disease 
experts.
 ► There will be less emphasis on synthesis of local 
and contextual data in this portion of the project.
 ► Synthesis of data from various systematic reviews 
will require close focus on research questions.
 ► Updates and de novo synthesis will need to focus on 
the most substantive evidence gaps.
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assessment (voluntary screening) and prevention (vacci-
nation) among newly arrived migrants. This guidance 
aims to support public health and health system profes-
sionals to screen and treat international migrants.2
Migrant populations include economic migrants, refu-
gees, asylum seekers and irregular migrants who may have 
been forced to flee conflict, natural disasters or economic 
peril.3 For the purposes of this evidence-based project, 
we define the target migrant population using health risk 
associated with recent arrival (eg, within 5 years of arrival 
in EU/EEA), country of origin, gender, and unaccom-
panied minors and other circumstances of migration.3 
Scoping literature reviews and a consensus meeting in 
Stockholm have selected a series of infectious diseases for 
systematic reviews: tuberculosis (TB) (active and latent), 
HIV, hepatitis B, hepatitis C, measles, mumps, rubella, 
diphtheria, tetanus, pertussis, Haemophilus influenzae type 
b, strongyloidiasis and schistosomiasis.
Infectious diseases endanger the health of both 
migrant and host populations. Interventions targeting 
both public health and health systems levels are needed 
to address these threats. The Migration Integration Policy 
Index health system survey showed that policies and 
programmes relevant for migrants are underdeveloped 
in many European countries.2 Key challenges identified 
by the survey include inadequate entitlements to health-
care, poor accessibility of services, lack of responsiveness 
to migrants’ specific needs, absence of interpretation 
services and lack of local health professional training.4
For decades, public health programmes have played 
an important role in assessing migrants for infectious 
diseases. Historically, port-of-entry approaches met ships 
on arrival and conducted screening and quarantine 
programmes.5 In recent decades, the sheer number of 
migrants and diverse modes of travel have reduced the 
effectiveness of this approach.6 Evidence from a series of 
evidence reviews in Canada on recent migrants showed 
that age, gender, forced migration and migrant country 
of origin often modified disease risk and helped guide 
assessment and prevention priorities.3 Evidence from 
international migrant health reviews have begun to influ-
ence public health policy and primary health clinical 
assessments, as seen in Ireland, Canada, Australia and the 
USA, for example.3 5–7
The objective of this suite of systematic reviews is to 
guide the identification, appraisal and synthesis of best 
available quantitative and qualitative evidence on preven-
tion and assessment (voluntary screening) of priority 
infectious diseases. This protocol follows the Preferred 
Reporting Items for Systematic Reviews and Meta-Anal-
yses for Protocols (PRISMA-P) guideline.
rAtIonAlE
The ECDC has invested in systematic reviews of public 
health voluntary screening and prevention for newly 
arriving migrants.8 9 Systematic reviews play an important 
role in synthesising evidence to address important 
questions in health and social programmes. Using stan-
dardised methods, review findings can contribute to new 
recommendations, trustworthiness of existing evidence 
and the identification of gaps in knowledge. System-
atic review protocols serve as explicit and transparent 
templates for the final review. Protocols minimise bias 
by determining the content of the process and content 
of the review. Publishing the protocol demonstrates to 
the reader that the methods have been thought out in 
advance and provides the reader with an opportunity to 
confirm the authors made critical decisions a priori.10 
Following the protocol accordingly and performing the 
review properly will identify the effects of interventions 
on the benefits and harms of health assessment (volun-
tary screening, treatment and vaccine prevention) in 
migrants. Below, we provide context overviews of each 
selected infectious disease; additional details on ratio-
nale, key questions and logic models for each infectious 
disease review can be found in the online supplementary 
appendices.
tuberculosis
TB causes significant morbidity and mortality in high-in-
come countries. Migrants from high TB incidence 
countries account for the vast majority of the TB case 
burden.1 11 12 Migrants originating from intermediate and 
high TB incidence countries are at increased risk of expo-
sure to TB and increased risk of developing active TB.6 
Individuals and overcrowded populations exposed to TB 
have an increased lifetime risk of developing active TB 
through reactivation of latent TB infection (LTBI) after 
arrival. Screening and treatment of active and latent TB 
are often components of TB control and elimination strat-
egies. Most Western European countries screen migrants 
for active TB on or soon after their arrival. However, for 
the migrant groups targeted, the TB incidence in migrant 
source countries and the setting vary.13–16 The effective-
ness and cost-effectiveness of these strategies are unclear. 
Given the relatively low yield of active TB screening 
programmes, there is a growing interest in latent TB 
screening and treatment for migrants to prevent the 
development of active TB.17 It is also unclear which 
migrants may benefit from LTBI screening and treatment 
and what would be the impact on health system's resource 
use and costs. The ECDC continues to work on TB elimi-
nation strategies and these include screening guidance17 
(see online supplementary appendix 1, supplementary 
appendix 1 figure 1 and supplementary appendix 1 figure 
2).
HIV
By the end of 2014, approximately 36.9 million people 
were living with HIV and/or AIDS, 2.6 million of whom 
were children under the age of 15 years. Sub-Saharan 
Africa bears the largest burden of HIV, where the number 
of HIV-infected people had reached 25.8 million in 201418 
and only 54% of infected people were aware of their posi-
tive status for HIV. In the same year, 1.2 million persons 
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around the world died due to HIV-related causes. In 2014, 
almost 30 000 people were diagnosed with HIV in EU/
EEA Member States, a rate of 6.4 cases in every 100 000 
people.19 In the EU, an estimated 30% of people living 
with HIV are unaware of their HIV infection.20 This is 
thought to be mainly due to the low uptake of and access 
to voluntary HIV testing and counselling. HIV is dispro-
portionately prevalent in LMICs, and thus refugees and 
other migrants coming from HIV endemic countries are 
at increased risk for this infection. The stigma attached 
to HIV and the potential for exclusion from immigration 
by some countries pose additional barriers and concerns 
for the migrants. Migrants face fears of HIV transmis-
sion, and impact of seropositive status on family, commu-
nity and individual/family costs, including loss of work 
time related to screening and treatment. This fear and 
stigma forces migrants to avoid HIV testing and to seek 
treatment.21 22 There is a need for evidence-based guid-
ance for screening approaches and treatment of migrant 
populations coming to the EU/EEA from HIV endemic 
areas (see online supplementary appendix 2 and supple-
mentary appendix 2 figure 1).
Hepatitis b
Hepatitis B virus (HBV) infection is an important global 
health problem that affects an estimated 240 million 
people worldwide and approximately 13 million in the 
WHO European region.5 23 Chronic HBV infection is 
frequently asymptomatic, but 20%–30% of patients with 
chronic hepatitis B (CHB) will develop complications, 
including liver cirrhosis and hepatocellular carcinoma 
(HCC). These complications result in 650 000 prema-
ture global deaths annually.24–26 An effective vaccine 
for hepatitis B has existed for several decades. In addi-
tion, new treatment options are increasingly effective at 
reducing the incidence of cirrhosis and HCC in patients 
with CHB.6 Although global vaccination rates have 
increased, the prevalence of CHB remains high in certain 
LMICs.7 26 Migrants to EU/EEA carry a disproportionate 
burden of CHB-related morbidity and mortality. Prac-
tices in screening and treatment for hepatitis B vary by 
country across Europe, with no standard EU/EEA guid-
ance for screening, vaccination and treatment.24 Impact 
on resource use and costs varies by country. Studying 
the effectiveness of screening and developing appropriate 
guidance for hepatitis B in migrants to Europe for whom 
to screen, vaccinate and treat are a priority for migrant 
health (see online supplementary appendix 3 and supple-
mentary appendix 3 figure 1).
Hepatitis c
Worldwide, between 120 and 170 million people are living 
with hepatitis C virus (HCV), with 15 million in the WHO 
European region.24 HCV is the leading cause of chronic 
liver disease, end-stage cirrhosis and liver cancer.6 It is esti-
mated that between 2 and 6.6 million individuals in the 
EU/EEA are infected with chronic HCV. HCV is one of 
the leading causes of chronic liver disease and cirrhosis, 
and the most common indication for liver transplantation 
in most European countries. Patients in early stages of the 
disease are generally asymptomatic, and therefore most 
patients present in the late stages of HCV disease, when 
treatments are less effective and complications or death 
are unavoidable.27 In recent years, highly effective but very 
expensive curative treatments have emerged. Early diag-
nosis and treatment may limit the burden of the disease 
in the EU/EEA, for example, screening migrants when 
HCV prevalence in their countries of origin is higher 
than those of European settlement countries.28 Defining 
high prevalence regions and determining the effective-
ness, acceptability, cost and affordability of screening and 
treatment from both an EU/EEA migrant and a public 
health perspective are necessary (see online supplemen-
tary appendix 4 and supplementary appendix 4 figure 1).
Vaccine-preventable diseases (measles, mumps, rubella 
(MMr vaccines), and diphtheria, tetanus, polio and pertussis, 
Haemophilus influenzae type b (dtPP-Hib vaccines))
In 2011, evidence-based clinical guidelines for migrants 
and refugees recommended vaccination for all adult 
immigrants without immunisation records with one dose 
of measles, mumps and rubella vaccine, and a primary 
series of tetanus, diphtheria and polio vaccines, to reduce 
associated morbidity and mortality.6 For children, the 
guidelines propose age-appropriate vaccination for those 
with absent or uncertain vaccination records.6 The low 
cost of vaccination is strongly favoured against potential 
morbidity and mortality costs associated with measles 
complications, congenital rubella syndrome, tetanus 
and severe pertussis in infants.29–33 Despite this recom-
mendation, engaging migrant populations in preventa-
tive health services remains a challenge. Factors include 
barriers to accessing healthcare, lack of health coverage 
in public programmes, inability to obtain private health 
insurance and documented immigration status, among 
others. Organisational barriers include availability of 
interpreters and cultural mediators, hours of operation, 
lack of information regarding services provided, as well 
as geographical and transportation challenges.34 Indi-
vidual-level barriers that include social isolation and lack 
of support networks, cultural aspects of belonging to an 
ethnic group, language barriers and discrimination were 
factors that migrants identified as making them vulner-
able, hindering access to care.34 This review will synthe-
sise evidence on safety, resource use including type of 
personnel (eg, nurses and health workers) and models 
of administering vaccinations, cost and implementation 
for EU/EEA (see online supplementary appendix 5 and 
supplementary appendix 5 figure 1).
Intestinal parasites
Schistosomiasis and strongyloidiasis affect between 30 
and 250 million persons in endemic regions. The health 
impact of these neglected intestinal parasitic diseases 
has recently gained prominence due to increased global 
migration and resettlement. For example, strongyloidiasis 
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Table 1 Eligibility criteria used for all diseases
Study characteristics Inclusion criteria
Population We will consider studies of any population, children and adults, which may be considered indirect 
evidence. We will use migrant data if available.
Interventions Screening, treatment and vaccine prevention interventions and programmes for one of the selected 
diseases being evaluated.
Comparisons No screening or prevention intervention/programmes comparison.
Outcomes Reduction in morbidity or mortality including surrogate outcomes or disease transmission.
Study characteristics Design: systematic reviews, defined as a review with selection criteria, and searching of at least one 
database.
and schistosomiasis both have the peculiarity of leading 
to severe chronic infections years after leaving endemic 
regions. Strongyloidiasis may be life-threatening in immu-
nocompromised patients, and schistosomiasis may lead to 
chronic and fatal complications such as cancer. The rates 
have significantly increased in previously non-endemic 
regions.6 Schistosoma haematobium can infest bodies of 
water in Southern Europe where intermediate competent 
host Bulinus (molluscum) is present. This could theoret-
ically lead to foci of transmission in the EU.35 Thus, there 
is a need to provide evidence-based guidance for volun-
tary testing and treatment that will reduce morbidity and 
mortality in high-risk migrant populations, in order to 
reduce transmission and out-of-pocket and health system 
costs, and to prevent the transmission of the infection. 
Defining high prevalence regions and determining the 
effectiveness, acceptability, resource use and cost-effec-
tiveness from both a migrant and an EU/EEA public 
health perspective are necessary (see online supplemen-
tary appendix 6, supplementary appendix 6 figure 1 and 
supplementary appendix 6 figure 2).
objEctIVE
The objective of this systematic review is to identify, 
appraise and synthesise the best available evidence on 
prevention and health assessment of selected infectious 
diseases among migrants to the EU/EEA. It will use 
a Cochrane-based approach and report on clinically 
important outcomes and Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) 
summary of findings tables and cost-effectiveness of 
interventions.36 We provide detailed key questions and 
outcomes for each of the disease reviews in the online 
supplementary appendices.
MEtHods
The Cochrane methodological approach described in 
this protocol for evidence-based literature searching 
conforms to the PRISMA for systematic review proto-
cols (PRISMA-P) as closely as possible.10 This suite of 
systematic reviews aims to conduct systematic reviews 
and to inform ECDC public health guidance. We will 
update and enhance anchoring evidence-based migrant 
evidence.36 This protocol outlines the methods approach 
to the systematic review. This approach follows the new 
GRADE Adolopment Approach, a systematic guideline 
development approach that combines adoption, adap-
tation, and as needed de novo development of reviews 
to address elements of the GRADE evidence to decision 
(EtD) framework.3 36–38
Within this overall systematic review, there are six 
infectious diseases working groups, each one evalu-
ating the evidence for one or more infectious disease 
topics. Each working group has developed key questions 
and prioritised clinically important outcomes. Groups 
then constructed a logic model considering children 
and adult migrant populations to explicitly outline the 
evidence pathway to guide the search and synthesis (see 
online supplementary appendices). All six subgroups will 
follow the review methods as described in this protocol. 
Each interdisciplinary group includes disease content 
experts, a European public health context expert and a 
GRADE methodologist; some groups include community 
organisations. The process is divided into four phases:
 ► Phase 1: conduct systematic review and appraisal of 
effectiveness reviews and evidence-based guidelines 
(ie, linked to systematic reviews).
 ► Phase 2: conduct systematic search and appraisal for 
economic evaluations on resource use and cost-effec-
tiveness, on each topic.
 ► Phase 3: update systematic reviews of effectiveness: 
search for, select, appraise and synthesise new trials 
and systematic reviews to update the existing system-
atic review.
 ► Phase 4: supplement with de novo systematic reviews: 
we will conduct new focused systematic reviews if 
there is promising evidence but no existing systematic 
reviews on a critical topic or question. These searches 
will focus on randomised and non-randomised trials.
Phase 1: conduct a systematic review of reviews and 
guidelines
Eligible studies for this review will include systematic 
reviews that meet the criteria described in table 1. We 
will not apply a language restriction in this protocol, and 
when we identify more than one version of a systematic 
review, the most recent one will be considered.
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Search strategy
An experienced health information specialist with exper-
tise in systematic review searching will develop electronic 
literature search strategies in consultation with infec-
tious disease working groups (see online supplementary 
appendix 7 for an example of a draft search strategy for 
one disease for one database). We will search Medline, 
Embase, Cumulative Index to Nursing and Allied Health 
Literature (CINAHL), Epistemonikos and Cochrane 
Central. The literature search will be restricted to studies 
published from 1 January 2010 to present. Our group 
published migrant health guidelines based on system-
atic reviews in 2011,6 and we will use these as anchoring 
evidence-based guidelines to supplement with new 
systematic review evidence. The search strategy will use a 
combination of indexed terms and free text words. Our 
previous searches6 demonstrated that refugees and other 
migrants are under-represented in randomised controlled 
trials and other intervention research. Migrants represent 
a very heterogeneous international population. When 
appropriate, we will consider studies on high-risk migrant 
groups, but in estimating effectiveness of interventions we 
will also consider studies on general populations. Later 
as we develop guidance, we will also collect evidence as 
we study migrant values on outcomes, acceptability, feasi-
bility and equity.
In addition, we will search grey literature for published 
guidelines and reports on screening and prevention 
programme on relevant organisations’ websites (eg, 
Centers for Disease Control and Prevention (CDC), 
ECDC, The Joint United Nations Programme on HIV/
AIDS (UNAIDS), WHO). The literature search results will 
be uploaded to a reference manager software package, to 
facilitate the study selection process.
Study screening and selection
Prior to the screening process, the review teams will 
undergo an exercise to facilitate consistency in study 
selection. The trained reviewers will screen in duplicate 
and independently screen the titles and abstracts of all 
retrieved citations to identify the eligible reviews. The full 
texts of potentially eligible citations (systematic reviews) 
will then be retrieved and screened independently in 
duplicate. During the systematic review, citations that 
are not reviews will be catalogued so they are available if 
needed at a later stage. The reviewers will compare the 
results and resolve disagreement by discussion or with 
help of third reviewer. We will contact authors of reviews 
once for missing information. If the reviewers are unable 
to find a meta-analysis relevant to the research question, 
but do find relevant individual studies within the review, 
then they will consider assessing the studies for inclusion.
Data extraction
We will develop a standardised extraction sheet for each 
condition-specific subgroup. We anticipate some consis-
tency across groups, especially with respect to how data 
are extracted, but there will be unique content aspects to 
each disease-specific data extraction as well. Prior to data 
extraction, reviewers will undergo a calibration exercise 
to ensure consistency. Teams of two reviewers will extract 
data in duplicate and independently. They will compare 
results and resolve disagreements by discussion or with 
help from a third reviewer. At a minimum we will extract 
(1) population, intervention, comparison and outcome 
elements of the research questions for interventional 
systematic reviews; (2) databases searched; (3) number of 
studies included in the systematic review; and (4) results 
(see online supplementary appendix 8 table 1). Data 
extraction will be modified if individual studies are found 
and included at this stage.
Risk of bias
We will assess the quality of the included systematic 
reviewers using the Scottish Intercollegiate Guide-
lines Network (SIGN 50) and ‘A Measurement Tool to 
Assess the Methodological Quality of Systematic Reviews 
(AMSTAR)’ tools (see online supplementary appendix 
8 table 2).39 Two reviewers will independently assess the 
quality in duplicate and disagreements will be resolved by 
discussion or using a third reviewer. We will also consider 
reporting of other forms of bias for systematic reviews of 
observational studies based on recommendations from 
the draft AMSTAR II (B Shea, personal communica-
tion, 2016). Quality assessment criteria will not be used 
to include or exclude studies but will be used to assess 
certainty in the findings. GRADE requires an assessment 
of the risk of bias. Information on the risk of bias for the 
individually included studies will be extracted according 
to the reporting in the included systematic reviews. Any 
individual studies will be assessed using Cochrane Risk of 
Bias tool or Newcastle-Ottawa Scale as appropriate.
Assessing the quality and certainty of the evidence
The GRADE criteria will be applied to assess the quality 
and certainty of evidence for the included studies. 
The rating is based on an assessment of (1) risk of bias 
(study limitation); (2) inconsistency (heterogeneity) in 
the direction and/or size of the estimates of effect; (3) 
indirectness of the body of evidence to the populations, 
interventions, comparisons and/or outcomes; (4) impre-
cisions of results (few participant/events/observations 
and/or wide CIs); and (5) other considerations (effect 
size and publication bias). The quality of evidence may be 
downgraded if there are serious or very serious concerns 
related to any of the GRADE criteria (see online supple-
mentary appendix 8 table 3). All key data will be entered 
in the GRADEpro software. This software will be used to 
produce GRADE evidence profile tables and summary of 
findings tables. If relevant, we will use the GRADE-CER-
Qual approach for summary of findings for outcomes for 
qualitative systematic reviews.40–42
Ranking of outcomes
In this protocol, we have identified and ranked all potential 
patient important outcomes (see online supplementary 
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appendix 8 table 4). Outcomes are ranked as critical, 
important but not critical, or limited importance for deci-
sion making. Only evidence on critical and important 
outcomes will be considered.
Phase 2: conduct a systematic search and selection for 
economic evaluations on resource use, costs and cost-
effectiveness
We will use cost-effectiveness studies identified from 
phase 1, and a librarian scientist will systematically 
search for economic evidence including resource use, 
costs and cost-effectiveness studies using Medline and 
Embase relating to our priority interventions. In addi-
tion, two health economists will systematically search 
the National Health System Economic Evaluation Data-
base, the Cost-Effectiveness Analysis Tuft’s registry and 
Google Scholar databases for economic studies. A sample 
PRISMA flow chart is provided for economic studies for 
TB (see online supplementary appendix 9). The health 
economists will screen the results for systematic reviews 
and primary studies of resource use, costs or cost-effec-
tiveness of screening and treating each of the priority 
infectious diseases, then independently screen the full-
text articles and assess the systematic reviews for quality 
using AMSTAR. Studies will not be excluded on the basis 
of AMSTAR scores. Data will be independently extracted 
from primary studies of resource use, costs or cost-effec-
tiveness aligned with the disease group’s aims, including 
GRADE EtD considerations around size of resource 
requirements, certainty of evidence of resources and 
cost-effectiveness favouring the intervention or compar-
ator. A one-page narrative summary of the economic 
evidence will be written, and evidence about the resource 
use and costs will be incorporated into the GRADE 
evidence profiles and summary of findings tables where 
appropriate.43
As economic evidence has not previously been 
reported in guidelines, we will systematically search all 
databases from inception to June 2016. Two reviewers 
will independently select, appraise and extract data. In 
case of disagreement, we will use discussion or a third 
reviewer. Evidence will be summarised for each of the 
infectious disease conditions. We will use AMSTAR for 
quality assessment of systematic reviews and GRADE to 
appraise certainty of evidence in the primary economic 
evaluations.
Phase 3: update systematic reviews of effectiveness
We will search for, select, appraise and synthesise new 
prospective trials and systematic reviews to update the 
existing systematic reviews. We will use the same search 
strategies as used in phase 1, but will consider trials as 
well as systematic reviews. We will search for intervention 
effectiveness dating 1 year prior to the publication of the 
most recent systematic reviews. We will appraise and eval-
uate the new evidence and we will integrate new evidence 
into the evidence summaries when feasible.
Phase 4: supplement with de novo systematic reviews
If no reviews are identified in phase 1 to address a critical 
disease or care delivery question, then a new systematic 
review will be performed to develop the guidance. Studies 
identified in this stage will be evaluated and synthesised 
using similar methods described previously. We will 
conduct a quality assessment using tools designed for 
individual studies, such as the Cochrane Risk of Bias tool 
for randomised trials44 or the Newcastle-Ottawa Scale for 
non-randomised studies.45 We will not use quality as sole 
eligibility criteria.
When possible, we will conduct a meta-analysis as part 
of the creation of GRADE summary of findings table. 
When not appropriate due to high levels of heteroge-
neity, we will synthesise and report the evidence using a 
narrative summary of findings format. The objective will 
be to report on the preselected benefits and harms associ-
ated with the interventions of interest.
developing guidance using evidence
All existing evidence selected and synthesised for inter-
ventions, including both benefits and harms, will be 
identified as evidence for GRADE summary of findings 
tables. We will select the most recent, the most relevant 
(based on European context and our logic model and 
questions) and the highest quality evidence. Evidence 
will come from systematic reviews and cost-effectiveness 
studies updates with randomised controlled trials. Where 
important gaps exist, we will address them with focused 
de novo systematic reviews.
dIssEMInAtIon
We will publish the separate systematic review in an 
open-access journal for public health stakeholders and/
or the GRADEpro database of evidence profiles ( dbep. 
gradepro. org). We will make the results available to 
panels of experts to use the evidence to develop inter-
national guidelines for migration. ECDC will publish 
a technical report, and we plan to submit a final guide-
line summary paper to a European clinical journal, 
for example, the British Medical Journal. We will use the 
ECDC, the International Conference on Ethnicity, Race 
and Migrant Health, our Campbell and Cochrane Collab-
oration Equity Methods website, and other social media 
to push out results.
dIscussIon
During the past 50 years, many national and some interna-
tional disease detection and control, immunisation, and 
communicable disease prevention strategies have been 
successful. Refugees and other migrants originating from 
countries with a high infectious disease burden could pose 
a challenge for national disease control and/or elimina-
tion strategies. Evidence-based guidelines are required 
to guide public health, non-governmental organisations 
and clinical sectors in the assessment and prevention of 
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infectious diseases for child and adult migrants to Europe. 
The results of our systematic review(s) will be of interest 
to a broad group of stakeholders, including policymakers, 
healthcare practitioners and members of international 
health organisations. Accessing and summarising the 
data using explicit, consistent and transparent methods 
provide a foundation for public health policy and guide-
lines.6 High-quality synthesis and dissemination of the 
evidence and updating and enhancing the 2011 system-
atic review6 will support a more coordinated approach to 
voluntary screening and treatment of infectious diseases 
in migrants in EU/EEA Member States. Our reviews will 
facilitate evidence-based management of migrants with 
the studied infectious diseases, and will likely identify key 
areas for future research, and provide a framework for 
conducting overviews of systematic reviews on causation.
We will use the evidence from these reviews to inform 
GRADE EtD criteria.38–42 46 These EtD summaries will 
also include data on migrants’ preferences, stakeholder 
acceptability and feasibility and health equity. These 
summaries will support an ECDC scientific panel in 
developing guidance statements on infectious diseases 
for newly arriving migrants to the EU/EEA. Details on 
GRADE EtD methods process will be published separately.
conclusIons
In this protocol, we detail a suite of linked systematic 
reviews of infectious disease conditions that may benefit 
from assessment for newly arriving child and adult 
migrants. The four-phase approach aims to identify, 
appraise and update existing systematic reviews, and iden-
tify critical gaps leading to opportunities for syntheses 
and de novo reviews. This review will provide high-quality 
evidence for the forthcoming ECDC Evidence-Based 
Guidance on Prevention and Assessment of Infectious 
Diseases for Migrants to the EU/EEA .
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